Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

CFO and COO

President and CEO

Chief Medical Officer

CEO & President

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor; and VRx-510, a preclinical-stage PDK-1 inhibitor. The company was formerly known as Sunesis Pharmaceuticals, Inc. and changed its name to Viracta Therapeutics, Inc. in February 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cance...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-02-27	Premium	sold	Premium	Premium	Premium	CFO and COO
2024-02-25	Premium	acquired	Premium	Premium	Premium	-
2024-02-25	Premium	acquired	Premium	Premium	Premium	-
2024-02-25	Premium	acquired	Premium	Premium	Premium	CFO and COO
2023-12-01	Premium	bought	Premium	Premium	Premium	President and CEO
2023-11-30	Premium	bought	Premium	Premium	Premium	President and CEO
2023-11-28	Premium	sold	Premium	Premium	Premium	CFO and COO
2023-11-25	Premium	acquired	Premium	Premium	Premium	-
2023-11-25	Premium	acquired	Premium	Premium	Premium	CFO and COO
2023-11-25	Premium	acquired	Premium	Premium	Premium	-
2023-08-28	Premium	sold	Premium	Premium	Premium	CFO and COO
2023-08-25	Premium	acquired	Premium	Premium	Premium	-
2023-08-25	Premium	acquired	Premium	Premium	Premium	-
2023-08-25	Premium	acquired	Premium	Premium	Premium	CFO and COO
2023-05-25	Premium	acquired	Premium	Premium	Premium	-
2023-05-25	Premium	acquired	Premium	Premium	Premium	-
2023-05-25	Premium	sold	Premium	Premium	Premium	CFO and COO
2023-05-25	Premium	acquired	Premium	Premium	Premium	CFO and COO
2023-02-27	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-02-27	Premium	sold	Premium	Premium	Premium	CFO and COO
2023-02-25	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2023-02-25	Premium	acquired	Premium	Premium	Premium	CFO and COO
2023-02-25	Premium	acquired	Premium	Premium	Premium	-
2023-02-25	Premium	acquired	Premium	Premium	Premium	-
2022-11-28	Premium	sold	Premium	Premium	Premium	Chief Medical Officer

VIRX - Viracta Therapeutics, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for VIRX